When was Grace Science founded?

Grace Science was founded in 2017.

Where is Grace Science located?

Grace Science is headquartered in Menlo Park, United States.

How many employees does Grace Science have?

As of Apr 30, 2026, the latest employee count at Grace Science is 15.

Is Grace Science a funded company?

Grace Science is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Grace Science rank among its competitors?

Grace Science ranks 1772nd amongst 3332 active competitors, of which 1150 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of Grace Science?

Grace Science's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Senti Bio secured the most recent funding round in May, 2026.

Grace Science - 2026 Company Profile, Team, Funding & Competitors

Company Details

Grace Science develops therapies for treating rare diseases and cancer. The rare disease is NGLY1 deficiency. The company is developing small molecules for the activity of NFE2L1 and similar proteins. They are also researching that cancer cells can sense the inhibition of the chemotherapies by activating the proteasome via the activation of NFE2L1 by NGLY1.

Website: gracesciencellc.com
Phone Number: +1 **********

Key Metrics

Founded Year

2017

Location

Menlo Park, United States

Stage

Funding Raised

Investors

JLABS

Ranked

1772^nd among 3332 active competitors

Employee Count

15 as on Apr 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3096 more

View Grace Science's full profile

Grace Science is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
GRACE SCIENCE, LLC CIN: 820767784 , United States, Active	Dec 31, 1999	-	13 (As on Dec 31, 2024)	-

Grace Science is a funded company. Grace Science has 1 institutional investor.

View details of Grace Science's funding rounds and investors

The founders of Grace Science are Matt Wilsey and Carolyn Bertozzi.

Here are the details of Grace Science's key team members:

Matt Wilsey: Co-Founder & CEO of Grace Science.
Carolyn Bertozzi: Co-Founder of Grace Science and founder of 1 other company.

View details of Grace Science's Founder profiles and Board Members

Grace Science's employee count trend

Grace Science has 15 employees as of Apr 26. Here is Grace Science's employee count trend over the years:

Uncover Grace Science's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Grace Science include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Grace Science, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	BioMarin Pharmaceutical 1997, San Rafael (United States), Public	Developer of therapeutics for the treatment of rare genetic diseases	$37.5M	MPM Capital, Temasek & 7 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
1772nd	Grace Science 2017, Menlo Park (United States), Funding Raised	Developer of therapies for treating rare disease and cancer	-	JLABS	31/100